Pain Coping Skills Training to Improve Pain and Poor Adherence caused by Aromatase Inhibitory-Associated Arthralgia in Breast Cancer Survivors, SKIP-Arthralgia Trial

Inclusion Criteria

• Female * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Aged 18 years or older * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Diagnosed with stage I-III hormone receptor positive (HR+) breast cancer * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * The indicated eligibility criterion may change over time, meaning that women who are not eligible at a given timepoint may become eligible later. When women are excluded based on one or more of these criteria, we will ask for their consent to recontact them for later potential enrollment
• Currently taking AI therapy (letrozole, exemestane, or anastrozole) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * For determining eligibility, these data will be verified in screening interview (self-report)
• Reporting musculoskeletal pain that developed or worsened since starting AI therapy * For determining eligibility, these data will be verified in screening interview (self-report)
• Reporting at least 15 days of pain in the past 30 days * For determining eligibility, these data will be verified in screening interview (self-report) * The indicated eligibility criterion may change over time, meaning that women who are not eligible at a given timepoint may become eligible later. When women are excluded based on one or more of these criteria, we will ask for their consent to recontact them for later potential enrollment
• A worst pain rating of 4 or more on an 11 point (0-10) numerical rating scale in the past week * For determining eligibility, these data will be verified in screening interview (self-report) * The indicated eligibility criterion may change over time, meaning that women who are not eligible at a given timepoint may become eligible later. When women are excluded based on one or more of these criteria, we will ask for their consent to recontact them for later potential enrollment
• Based on known factors affecting their prognosis, patient is likely to be able to complete the study protocol * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• English proficient * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * For determining eligibility, these data will be verified in screening interview (self-report)
• If participants are taking analgesics, they must be on a stable analgesic regimen for at least 14 days prior to enrollment and should not have planned upward dose titration of their analgesics during the study period. (Note: Patients may elect to decrease their analgesic use during the study as per discussion with their provider. Unexpected dose adjustments including dose escalations due to unforeseen clinical need is allowed. Cannabis taken for pain relief would qualify as an analgesic) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * For determining eligibility, these data will be verified in screening interview (self-report) * The indicated eligibility criterion may change over time, meaning that women who are not eligible at a given timepoint may become eligible later. When women are excluded based on one or more of these criteria, we will ask for their consent to recontact them for later potential enrollment
• Comfortable using a tablet computer, a computer, or a smartphone to access online training * For determining eligibility, these data will be verified in screening interview (self-report)

Exclusion Criteria

• Evidence of metastatic disease * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Other active cancer (with the exception of non-melanoma skin cancer) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * For determining eligibility, these data will be verified in screening interview (self-report)
• Completed chemotherapy or radiation therapy less than four weeks prior to enrollment (these treatments can cause temporary exacerbation of musculoskeletal symptoms that typically resolve spontaneously) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician)
• Completed surgery less than 8 weeks prior to enrollment (because surgery can cause temporary post-surgical pain that typically resolves in this period of time); minor surgeries may be allowed more recently than 8 weeks at the discretion of the study team * For determining eligibility, these data will be verified in screening interview (self-report) * The indicated eligibility criterion may change over time, meaning that women who are not eligible at a given timepoint may become eligible later. When women are excluded based on one or more of these criteria, we will ask for their consent to recontact them for later potential enrollment
• Have diagnosed or suspected condition that would interfere with informed consent or completion of study activities (e.g., significant impairment in cognition or uncorrected hearing/vision) * For determining eligibility, these data will be ascertained with medical records (and, when appropriate, verification of treating clinician) * For determining eligibility, these data will be verified in screening interview (self-report)